Biogen upgraded to Buy with $335 price target at Canaccord. As reported previously, Canaccord analyst Sumant Kulkarni upgraded Biogen to Buy from Hold. The analyst said although there are risks that remain, the company’s financial flexibility makes him more positive on the shares. He sees ample business opportunity while the MS and Spinraza dynamics are key variables. Kulkarni likes the current valuation but lowered his price target to $335 from $350 on Biogen to account for a more conservative outlook on revenues
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.